Styrning Novo Nordisk A/S

NOVO B

DK0062498333

Farmaceutiska produkter

Marknaden stängd - Nasdaq Copenhagen Andra börsplatser 17.20.00 2025-12-12			5-dagars förändring	Förändring 1 jan.
321,15 ^DKK	+0,45 %		+3,73 %	−48,55 %

12-12	Europeiska aktier handlade som amerikanska depåbevis sjunker i fredagens handel - aktierna fortfarande upp denna vecka	MT
12-12	Novo Nordisk står inför en begränsad risk från Lillys Retatrutide

Verkställande utskott: Novo Nordisk A/S

Verkställande direktör

Innehade positionerSedan

Maziar Mike Doustdar

55 år

Chief Executive Officer	2025-08-07
President	2025-08-07

Tania Sabroe

48 år

Human Resources Officer

2022-01-01

Martin Lange

55 år

Chief Tech/Sci/R&D Officer

2025-08-07

Robin Evers

General Counsel

2024-03-01

Karsten Munk Knudsen

54 år

Director of Finance/CFO

2018-02-15

Sammansättning av styrelsen: Novo Nordisk A/S

Direktör

KommittéerSedan

Lars Rebien Sørensen

71 år

Chairman

2025-11-14

Stephan Engels

63 år

Compensation Committee	2025-11-14
HR Committee	2025-11-14
Governance Committee	2025-11-14
Audit Committee Chair	2025-11-14

Kasim Kutay

60 år

HR Committee	2017-03-23
Governance Committee	2017-03-23
Compensation Committee	2024-01-29
Nominating Committee	2024-01-29

Cees de Jong

64 år

Audit Committee	2025-11-14
Compensation Committee	2024-01-29
Nominating Committee	2024-01-29
Compensation Committee Chair	2025-11-14

Thomas Rantzau

53 år

HR Committee	2018-03-22
Governance Committee	2018-03-22

Mette Bøjer Jensen

50 år

Audit Committee

2022-03-01

Elisabeth Christensen

60 år

Compensation Committee

2022-03-24

Britt Meelby Jensen

52 år

Audit Committee

2025-11-14

Liselotte Hyveled

59 år

Director/Board Member

2022-03-24

Senaste Tillsättningar: Novo Nordisk A/S

12-02	Pressöversikt - Kanada - 2 december	RE
11-17	Hims & Hers utser tidigare FDA-tjänsteman Deb Autor till första policychef	RE
11-14	Novo Nordisk väljer ny ordförande och vice ordförande	MT
11-14	Novo Nordisk A/S godkänner nya styrelseledamöter	CI
11-14	Novo Nordisk utser ny styrelseordförande och vice ordförande vid omfattande styrelseförändring	MT
11-14	Novo Nordisks nya ordförande ser OTC-framtid för Wegovy när huvudägaren stärker sitt grepp	RE
11-14	Pfizers tidigare FoU-chef Dolsten drar tillbaka sin kandidatur till Novo Nordisks styrelse	RE

Mer nyheter

Före detta tjänstemän och direktörer: Novo Nordisk A/S

Insider

Innehade positioner

SedanTill

Stig Strøbæk

Director/Board Member

1998-01-01

2022-03-24

Anne Marie Handrup Kverneland

Director/Board Member

2000-01-01

2022-03-24

Mads Krogsgaard Thomsen

Director/Board Member	2011-02-18	2011-11-09
Chief Tech/Sci/R&D Officer	2000-11-01	2021-03-01

Jesper Brandgaard

Director of Finance/CFO	2000-11-01	2018-02-15
General Counsel	2018-02-15	2019-04-01

Göran Albert Ando

Director/Board Member	2005-01-01	2013-03-20
Chairman	2013-03-20	2018-01-01
Chief Tech/Sci/R&D Officer	2010-06-08	2011-11-08

Kåre Schultz

Chief Operating Officer	2010-06-08	2015-04-30
President	1989-01-01	2015-04-30

Hannu Ragnvald Ryöppönen

Director/Board Member	2009-03-01	2015-03-19
Independent Dir/Board Member	2011-08-16	2015-03-19

Lise Kingo

Human Resources Officer	2011-11-09	2014-11-01
Corporate Officer/Principal	2010-06-08	2011-11-09

Sten Scheibye

Chairman	2003-01-01	2013-03-20
Independent Dir/Board Member	2003-01-01	2012-05-02

Per Toft Valstorp

Corporate Officer/Principal

2009-07-09

2013-01-01

Jørgen Wedel

Director/Board Member

2000-01-01

2012-03-21

Pamela Kirby

Director/Board Member

2008-01-01

2011-03-23

Johnny Henriksen

Director/Board Member

2010-03-24

Ulrik Joakim Hjulmand-Lassen

Director/Board Member

2010-03-30

Kurt W. Briner

Director/Board Member

2009-03-18

Peter Gerhardsson

Corporate Officer/Principal

2008-05-01

Niels Jacobsen

Director/Board Member

2000-01-01

2008-01-01

Jan Ulf Sigvar J. Johansson

Director/Board Member

1998-01-01

2005-03-01

Henrik Gürtler

Director/Board Member

2005-01-01

Finn M. Ulrich

Chief Tech/Sci/R&D Officer

1996-01-01

2004-01-01

Robert Frederick Caspari

Corporate Officer/Principal

2004-01-01

Marianne Kock

Corporate Officer/Principal

1985-01-01

2002-01-01

Jack Nielsen

Corporate Officer/Principal

1990-01-01

2001-01-01

Valeta A. Gregg

Corporate Officer/Principal

1996-01-01

2001-01-01

Grethe Nørskov Rasmussen

Corporate Officer/Principal

1989-01-01

Kirsten Drejer

Corporate Officer/Principal

1991-01-01

2000-01-01

Anders Hedegaard

Sales & Marketing

1991-01-01

2000-01-01

Martin Olin

Director of Finance/CFO

1996-01-01

2000-01-01

Thomas Feldthus

Corporate Officer/Principal

1996-01-01

1999-01-01

Christian Hansen

Corporate Officer/Principal

1992-01-01

1999-01-01

Hanne Jensen

Corporate Officer/Principal

1995-01-01

1999-01-01

Jan Öhrström

Sales & Marketing

1990-01-01

1999-01-01

Anker Gunvald Lundemose

Corporate Officer/Principal

1994-06-01

1998-11-01

Peter Nordkild

Corporate Officer/Principal

1996-01-01

Harry Penner

General Counsel	1985-01-01	1988-01-01
Corporate Officer/Principal	1988-01-01	1993-01-01

Carsten Hellmann

Corporate Officer/Principal	1996-01-01	-
Sales & Marketing	1993-01-01	1995-12-31

Leif Kongerslev

Corporate Officer/Principal

1989-01-01

Johan Selmer

Corporate Officer/Principal

1983-01-01

Jørgen Ulrik Vejlsgaard

Corporate Officer/Principal

Torben Nissen

Corporate Officer/Principal

Lotte Sønderbjerg

Corporate Secretary

Mads Fischer Rasmussen

Corporate Officer/Principal

Søren Bregenholt

Chief Investment Officer	2010-06-09	-
Corporate Officer/Principal	-	2010-06-09

Ib Schneider

Corporate Officer/Principal

Kenneth William Harlow

Corporate Officer/Principal

Stephen Farr

Chief Tech/Sci/R&D Officer

Karin Hannader

Corporate Officer/Principal

Niels Jonas Heilskov Graversen

Corporate Officer/Principal

Casper Breum

Corporate Officer/Principal

Thue Walter Schwartz

Chief Tech/Sci/R&D Officer

Mads Dall

Corporate Officer/Principal

Ganesh Iyer

Corporate Officer/Principal

Pál Helmich

Corporate Officer/Principal

Tim Kehling Pedersen

Corporate Officer/Principal

Thomas Lander

Corporate Officer/Principal

Lene Gerlach

Corporate Officer/Principal

Jens Ole Pedersen

Corporate Officer/Principal

Christian Hemmingsen

Corporate Officer/Principal

Jens Morten Fogh

Chief Tech/Sci/R&D Officer

Patrick Michael Round

Corporate Officer/Principal

Claus Kühl

Corporate Officer/Principal

Jaques Arend

Corporate Officer/Principal

Martin O. Andersen

Director of Finance/CFO

Mads Buhl Axelsen

Corporate Officer/Principal

Grith Hagel

Corporate Officer/Principal

Mads Veggerby Lausten

Public Communications Contact

Sam Lindgren

Corporate Officer/Principal

Steen Klysner

Corporate Officer/Principal

Joe A. Young

Sales & Marketing

Jens Frederik Lage Hansen

Sales & Marketing

Mike Rulis

Public Communications Contact

Hans Schambye

Corporate Officer/Principal

Esper Boel

Corporate Officer/Principal

Niels Hvid

Corporate Officer/Principal

Bolette Wildt

General Counsel	-	2011-07-14
Corporate Officer/Principal	2011-07-14	-

Mogens Vang Rasmussen

Corporate Officer/Principal

Anders Pedersen

Corporate Officer/Principal

Michael J. Dwyer

Sales & Marketing

Jakob Dynnes Hansen

Corporate Officer/Principal

Peter W. Ravn

Corporate Officer/Principal

Jeppe Vesti Christensen

Corporate Officer/Principal

Per Bo Pedersen Fischer

Corporate Officer/Principal

Mads Øvlisen

Chairman

Stephan Christgau

Chief Tech/Sci/R&D Officer

Christian Meyer

Corporate Officer/Principal

Henrik Dalbøge

Corporate Officer/Principal

Ole Thastrup

Corporate Officer/Principal

Jürgen Langhärig

Corporate Officer/Principal

Tina Kragh-Jakobsen

Corporate Officer/Principal

Åldersfördelning av chefer

Könspartitet

Man	18
Kvinna	10

Vars verkställande kommitté

Man	4
Kvinna	1

Varav Direktörer

Man	5
Kvinna	4

Revisioner

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Nej

Controverses sur les droits de l'Homme

Nej

Controverses Subventions fiscales

Nej

Conforme à la finance Islamique

Novo Nordisk A/S är specialiserat på design, tillverkning och marknadsföring av farmaceutiska produkter. Nettoomsättningen fördelar sig per produktfamilj enligt följande: - Produkter för behandling av diabetes och fetma (93,6%); - Produkter för behandling av sällsynta sjukdomar (6,4%): avsedda för behandling av hemofili, blodsjukdomar, hormonella störningar etc. Nettoomsättningen fördelar sig geografiskt enligt följande: Europa/Mellanöstern/Afrika (20,8%), USA (57,6%), Nordamerika (3,7%), Kina (6,4%) och övriga (11,5%).

Anställda

78 554

Sektor

Farmaceutiska produkter

Kalender

02-04 - Q4 2025

Mer information om företaget